5-HT1A targeting PARCEST agent DO3AM-MPP with potential for receptor imaging: Synthesis, physico-chemical and MR studies

ANJU, -; Chaturvedi, Shubhra; Chaudhary, Vishakha; Pant, Pawan Kumar; Jha, Preeti; Kumaran, Senthil; Hussain, Firasat; Mishra, Anil K.

doi:10.1016/j.bioorg.2020.104487

Bioorganic Chemistry

2021

DOI: 10.1016/j.bioorg.2020.104487

|View full text |Cite

5-HT1A targeting PARCEST agent DO3AM-MPP with potential for receptor imaging: Synthesis, physico-chemical and MR studies

- ANJU

Shubhra Chaturvedi

Vishakha Chaudhary

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands

Giorgioni,

Bonifazi,

Botticelli

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

Abstract5‐HT1A receptor (5‐HT1A‐R) is a serotoninergic G‐protein coupled receptor subtype which contributes to several physiological processes in both central nervous system and periphery. Despite being the first 5‐HT‐R identified, cloned and studied, it still represents a very attractive target in drug discovery and continues to be the focus of a myriad of drug discovery campaigns due to its involvement in numerous neuropsychiatric disorders. The structure‐activity relationship studies (SAR) performed over the last years have been devoted to three main goals: (i) design and synthesis of 5‐HT1A‐R selective/preferential ligands; (ii) identification of 5‐HT1A‐R biased agonists, differentiating pre‐ versus post‐synaptic agonism and signaling cellular mechanisms; (iii) development of multitarget compounds endowed with well‐defined poly‐pharmacological profiles targeting 5‐HT1A‐R along with other serotonin receptors, serotonin transporter (SERT), D2‐like receptors and/or enzymes, such as acetylcholinesterase and phosphodiesterase, as a promising strategy for the management of complex psychiatric and neurodegenerative disorders. In this review, medicinal chemistry aspects of ligands acting as selective/preferential or multitarget 5‐HT1A‐R agonists and antagonists belonging to different chemotypes and developed in the last 7 years (2017–2023) have been discussed. The development of chemical and pharmacological 5‐HT1A‐R tools for molecular imaging have also been described. Finally, the pharmacological interest of 5‐HT1A‐R and the therapeutic potential of ligands targeting this receptor have been considered.

show abstract

Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands

Giorgioni,

Bonifazi,

Botticelli

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

5-HT1A targeting PARCEST agent DO3AM-MPP with potential for receptor imaging: Synthesis, physico-chemical and MR studies

Cited by 1 publication

References 36 publications

Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands

Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands

Contact Info

Product

Resources

About